12 results on '"Muss, Hyman B."'
Search Results
2. Case 15-2010.
- Author
-
Muss, Hyman B., D'Alessandro, Helen Anne, and Brachtel, Elena F.
- Subjects
- *
BREAST cancer patients , *CANCER in women , *DISEASES in older women , *GASTROESOPHAGEAL reflux , *HYPERCHOLESTEREMIA , *DOPPLER ultrasonography , *NEEDLE biopsy - Abstract
The article presents a case study of an 85-year-old woman with mammographically detected early breast cancer. The woman was suffering from several diseases including gastric esophageal reflux disease, chronic obstructive pulmonary disease, and hypercholesterolemia. There were several examinations performed including Doppler ultrasonogram, cytologic examination, and fine-needle aspiration. Results of the examinations indicated the presence of estrogen-receptor protein and progesterone-receptor protein in the tumor cells.
- Published
- 2010
- Full Text
- View/download PDF
3. Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer.
- Author
-
Muss, Hyman B., Berry, Donald A., Cirrincione, Constance T., Theodoulou, Maria, Mauer, Ann M., Kornblith, Alice B., Partridge, Ann H., Dressler, Lynn G., Cohen, Harvey J., Becker, Heather P., Kartcheske, Patricia A., Wheeler, Judith D., Perez, Edith A., Wolff, Antonio C., Gralow, Julie R., Burstein, Harold J., Mahmood, Ahmad A., Magrinat, Gutav, Parker, Barbara A., and Hart, Ronald D.
- Subjects
- *
DRUG therapy , *CANCER in women , *BREAST cancer research , *HEALTH of older women , *CLINICAL medicine research , *MEDICAL care research - Abstract
The article presents a study on the effectiveness of capecitabine therapy compared to standard chemotherapy in older women with breast cancer. The women involved in the study were 65 years old or older with varying stages of cancer and were randomly assigned to one of the therapies. The standard chemotherapy was selected by the patient with her physician from a choice of cyclophosphmide, methotrexate, and fluorouracil or doxorubicin plus cyclophosphamide. The results revealed that patients who were treated with capecitabine were more likely to relapse or die than those treated with standard chemotherapy.
- Published
- 2009
- Full Text
- View/download PDF
4. Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer.
- Author
-
Chapman, Judith-Anne W., Meng, Daniel, Shepherd, Lois, Parulekar, Wendy, Ingle, James N., Muss, Hyman B., Palmer, Michael, Changhong Yu, and Goss, Paul E.
- Subjects
CANCER in women ,BREAST cancer ,ADJUVANT treatment of cancer ,CANCER treatment ,HORMONE therapy ,TAMOXIFEN - Abstract
Background Older women with early-stage breast cancer experience higher rates of non-breast cancer-related death. We examined factors associated with cause-specific death in a large cohort of breast cancer patients treated with extended adjuvant endocrine therapy. Methods In the MA.17 trial, conducted by the National Cancer Institute of Canada Clinical Trials Group, 5170 breast cancer patients (median age = 62 years; range = 32-94 years) who were disease free after approximately 5 years of adjuvant tamoxifen treatment were randomly assigned to treatment with letrozole (2583 women) or placebo (2587 women). The median follow-up was 3.9 years (range = 0-7 years). We investigated the association of 11 baseline factors with the competing risks of death from breast cancer, other malignancies, and other causes. All statistical tests were two-sided likelihood ratio criterion tests. Results During follow-up, 256 deaths were reported (102 from breast cancer, 50 from other malignancies, 100 from other causes, and four from an unknown cause). Non-breast cancer deaths accounted for 60% of the 252 known deaths (72% for those ≥70 years and 48% for those <70 years). Two baseline factors were differentially associated with type of death: cardiovascular disease was associated with a statistically significant increased risk of death from other causes (P = .002), and osteoporosis was associated with a statistically significant increased risk of death from other malignancies (P = .05). An increased risk of breast cancer-specific death was associated with lymph node involvement (P < .001). Increased risk of death from all three causes was associated with older age (P < .001). Conclusions Non-breast cancer-related deaths were more common than breast cancer-specific deaths in this cohort of 5-year breast cancer survivors, especially among older women. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
5. Cyclin D-1, Interleukin-6, HER-2/ neu, Transforming Growth Factor Receptor-II and Prediction of Relapse in Women with Early Stage, Hormone Receptor-Positive Breast Cancer Treated with Tamoxifen.
- Author
-
Muss, Hyman B., Bunn, Janice Yanushka, Crocker, Abigail, Plaut, Karen, Koh, James, Heintz, Nick, Rincon, Mercedes, Weaver, Donald L., Tam, Diane, Beatty, Barbara, Kaufman, Peter, Donovan, Michael, Verbel, David, and Weiss, Linda
- Subjects
- *
CANCER patients , *CANCER in women , *GROWTH factors , *ESTROGEN antagonists , *ANTINEOPLASTIC agents , *TAMOXIFEN , *INTERLEUKIN-6 , *BREAST cancer - Abstract
We hypothesized that amplification or overexpression of HER-2 (c-erbB-2), the Ki-67 antigen (Mib1), cyclin D-1 (CD1), interleukin-6 (IL-6), or the transforming growth factor beta II receptor, (TGFβRII), would predict relapse in women with early stage, estrogen (ER) and/or progesterone receptor (PR) positive breast cancer treated with tamoxifen. Conditional logistic regression models and a new novel analytic method––support vector machines (SVM) were used to assess the effect of multiple variables on treatment outcome. All patients had stage I–IIIa breast cancer (AJCC version 5). We paired 63 patients who were disease-free on or after tamoxifen with 63 patients who had relapsed (total 126); both disease-free and relapsed patients were matched by duration of tamoxifen therapy and time to recurrence. These 126 patients also served as the training set for SVM analysis and 18 other patients used as a validation set for SVM. In a multivariate analysis, larger tumor size, increasing extent of lymph node involvement, and poorer tumor grade were significant predictors of relapse. When HER-2 or CD1 were added to the model both were borderline significant predictors of relapse. The SVM model, after including all of the clinical and marker variables in the 126 patients as a training set, correctly predicted relapse in 78% of the 18 patient validation samples. In this trial, HER-2 and CD1 proved of borderline significance as predictive factors for recurrence on tamoxifen. An SVM model that included all clinical and biologic variables correctly predicted relapse in >75% of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
6. Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen.
- Author
-
Kimmick, Gretchen G., Lovato, James, McQuellon, Richard, Robinson, Emily, and Muss, Hyman B.
- Subjects
BREAST cancer ,SERTRALINE ,CANCER in women ,CANCER treatment ,PLACEBOS ,CANCER research - Abstract
We observed the relief of hot flashes in breast cancer survivors taking tamoxifen and treated with sertraline for depression. Our objective was to assess the effect of sertraline on the frequency and severity of hot flashes, mood status, and health-related quality of life. We used a randomized, double-blind, placebo-controlled, crossover study using 6 weeks of sertraline (50 mg each morning) versus placebo. Study participants were 62 breast cancer survivors from an oncology clinic in a tertiary care center on adjuvant tamoxifen reporting bothersome hot flashes. Patients were asked to keep a daily hot flash diary to record hot flash frequency and severity, from which hot flash scores (frequency × severity) were calculated. The Center for Epidemiologic Studies depression scale and Functional Assessment of Cancer Therapy—Breast (FACT-B) (at baseline, 6 weeks, and 12 weeks) were used to assess mood and quality of life. Sixty-two women were accrued. Forty-seven women (median age 53.9 years, range 36.6–77.1 years; 89% postmenopausal; 85.5% Caucasian) completed the first 6 weeks and 39 completed 12 weeks. The baseline daily hot flash frequency and score were 5.8 (standard deviation 4.1) and 11.5 (14.0), respectively. At the end of the first 6 weeks, hot flash frequency decreased by 50% in 36% of those taking sertraline compared to 27% taking placebo. In the crossover analysis, sertraline was significantly more effective than placebo: women crossing from placebo to sertraline had a decrease (−0.9 and −1.7) in hot flash frequency and score, whereas those crossing from sertraline to placebo had an increase (1.5 and 3.4) in hot flash frequency and score (p = 0.03 and 0.03). Forty-eight percent preferred the sertraline period, 11% preferred the placebo period, and 41% had no preference (p = 0.006). Measures of depression and quality of life were within normal range and did not change significantly within treatment groups. Sertraline decreases hot flashes in breast cancer survivors taking tamoxifen and women prefer sertraline to placebo. Further study of sertraline for the management of hot flashes is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
7. Update in Medical Oncology for Older Patients: Focus on Breast Cancer: Management of Early Breast Cancer.
- Author
-
Witherby, S. M. and Muss, Hyman B.
- Subjects
BREAST cancer ,CANCER in women ,OLDER women ,DRUG receptors ,IMMUNOLOGICAL adjuvants ,TUMORS ,ONCOLOGY - Abstract
Breast cancer is a disease of older women, and its inci- dence continues to rise with the growth and aging of the U.S. population. Elderly women have frequently been under- treated and have been poorly represented in clinical breast cancer trials. We reviewed the literature on early breast cancer in older women. We present current information on the tumor biology of elderly women and the role of surgical therapy and adjuvant treatment with hormonal therapy, chemotherapy, biologic agents, and radiation therapy in its management. Lastly, we discuss the importance of clinical trials in the elderly and future directions for therapy. (Cancer J 2005;11:506-51 7) [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
8. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17.
- Author
-
Goss, Paul E., Ingle, James N., Martino, Silvana, Robert, Nicholas J., Muss, Hyman B., Piccart, Martine J., Castiglione, Monica, Dongsheng Tu, Shepherd, Lois E., Pritchard, Kathleen I., Livingston, Robert B., Davidson, Nancy E., Norton, Larry, Perez, Edith A., Abrams, Jeffrey S., Cameron, David A., Palmer, Michael J., and Pater, Joseph L.
- Subjects
TAMOXIFEN ,ANTINEOPLASTIC agents ,ADJUVANT treatment of cancer ,BREAST cancer ,IMMUNOLOGICAL adjuvants ,CANCER in women ,ESTROGEN - Abstract
Background: Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether extended adjuvant therapy with the aromatase inhibitor letrozole after tamoxifen reduces the risk of such late recurrences, was stopped early after an interim analysis showed that letrozole improved disease-free survival. This report presents updated findings from the trial. Methods: Postmenopausal women completing 5 years of tamoxifen treatment were randomly assigned to a planned 5 years of letrozole (n = 2593) or placebo (n = 2594). The primary endpoint was disease-free survival (DFS); secondary endpoints included distant disease-free survival, overall survival, incidence of contralateral tumors, and toxic effects. Survival was examined using Kaplan-Meier analysis and log-rank tests. Planned subgroup analyses included those by axillary lymph node status. All statistical tests were two-sided. Results: After a median follow-up of 30 months (range = 1.5–61.4 months), women in the letrozole arm had statistically significantly better DFS and distant DFS than women in the placebo arm (DFS: hazard ratio [HR] for recurrence or contralateral breast cancer = 0.58, 95% confidence interval [CI] = 0.45 to 0.76; P«.001; distant DFS: HR = 0.60, 95% CI = 0.43 to 0.84; P = .002). Overall survival was the same in both arms (HR for death from any cause = 0.82, 95% CI = 0.57 to 1.19; P = .3). However, among lymph node-positive patients, overall survival was statistically significantly improved with letrozole (HR = 0.61, 95% CI = 0.38 to 0.98; P = .04). The incidence of contralateral breast cancer was lower in women receiving letrozole, but the difference was not statistically significant. Women receiving letrozole experienced more hormonally related side effects than those receiving placebo, but the incidences of bone fractures and cardiovascular events were the same. Conclusion: Letrozole after tamoxifen is well-tolerated and improves both disease-free and distant disease-free survival but not overall survival, except in node-positive patients. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
9. Adjuvant Chemotherapy in Older and Younger Women With Lymph Node–Positive Breast Cancer.
- Author
-
Muss, Hyman B., Woolf, Susan, Berry, Donald, Cirrincione, Constance, Weiss, Raymond B., Budman, Daniel, Wood, William C., Henderson, I. Craig, Hudis, Clifford, Winer, Eric, Cohen, Harvey, Wheeler, Judith, and Norton, Larry
- Subjects
- *
BREAST cancer , *CANCER in women , *THERAPEUTICS , *DRUG therapy , *DISEASES , *LYMPH nodes , *WOMEN'S health - Abstract
Context Adjuvant chemotherapy improves survival for patients with local-regional breast cancer, but healthy older patients at high risk of recurrence are frequently not offered adjuvant chemotherapy, and the benefit of adjuvant chemotherapy in older patients is uncertain. Objective To compare the benefits and toxic effects of adjuvant chemotherapy among breast cancer patients in age groups of 50 years or younger, 51 to 64 years, and 65 years or older. Design and Setting Retrospective review of data from 4 randomized trials that accrued patients from academic and community medical centers between 1975 and 1999. Median follow-up for all patients was 9.6 years. All trials randomized patients to different regimens, doses, schedules, and durations of chemotherapy and all had a treatment arm with doses or schedules that were regarded to be "high" and potentially more toxic. Patients A total of 6487 women with lymph node--positive breast cancer; 542 (8%) patients were 65 years or older and 159 (2%) were 70 years or older. Main Outcome Measure Comparison of disease-free survival, overall survival, and treatment-related mortality among different age groups. Results Multivariate analysis showed that smaller tumor size, fewer positive lymph nodes, more chemotherapy, and tamoxifen use were all significantly (P<.001) related to longer disease-free and overall survival. There was no association between age and disease-free survival. Overall survival was significantly (P<.001) worse for patients aged 65 or older because of death from causes other than breast cancer. Thirty-three deaths (0.5% of all patients) were attributed to treatment, and older women had higher treatment-related mortality. Older women and younger women derived similar reductions in breast cancer mortality and recurrence from regimens containing more chemotherapy. Conclusion Age alone should not be a contraindication to the use of optimal chemotherapy regimens in older women who are in good general health. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
10. c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer.
- Author
-
Muss, Hyman B., Thor, Ann D., Berry, Donald A., Kute, Timothy, Liu, Edison T., Koerner, Frederick, Cirrincione, Constance T., Budman, Daniel R., Wood, William C., Barcos, Maurice, and Henderson, I. Craig
- Subjects
- *
BREAST cancer treatment , *CANCER in women , *ADJUVANT treatment of cancer , *RANDOMIZED controlled trials , *CLINICAL trials , *DOXORUBICIN , *FLUOROURACIL , *CANCER treatment , *ANTHRACYCLINES - Abstract
Background: The role of molecular markers in predicting the response to treatment of breast cancer is poorly defined. The Cancer and Leukemia Group B (CALGB) conducted a randomized adjuvant-chemotherapy trial (CALGB 8541) comparing three doses (high, moderate, and low) of cyclophosphamide, doxorubicin, and fluorouracil in 1572 women with node-positive breast cancer. This study (CALGB 8869) was designed to determine whether the DNA index, the S-phase fraction, c-erbB-2 expression, or p53 accumulation could be used as a marker to identify a subgroup of patients more likely than others to benefit from high doses of chemotherapy. Methods: Tissue blocks were obtained from 442 patients randomly selected from the larger CALGB trial. Paraffin sections from the primary lesions were analyzed for DNA content, S-phase fraction, c-erbB-2 expression, and p53 accumulation. Results: Patients randomly assigned to the high-dose regimen of adjuvant chemotherapy had significantly longer disease-free and overall survival if their tumors had c-erbB-2 overexpression. No further information was gained by adding the data on S-phase fraction or p53 accumulation to the analysis. There was no clear evidence of a dose-response effect in patients with minimal or no c-erbB-2 expression. Conclusions: There is a significant dose-response effect of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil in patients with overexpression of c-erbB-2 but not in patients with no c-erbB-2 expression or minimal c-erbB-2 expression. Overexpression of c-erbB-2 may be a useful marker to identify the patients who are most likely to benefit from high doses of adjuvant chemotherapy. (N Engl J Med 1994;330:1260-6.) [ABSTRACT FROM AUTHOR]
- Published
- 1994
- Full Text
- View/download PDF
11. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
- Author
-
Albain, Cathy S., Barlow, William E., Ravdin, Peter M., Farrar, William B., Burton, Gary V., Ketchel, Steven J., Cobau, Charles D., Levine, Ellis G., Ingle, James N., Pritchard, Cathleen I., Lichter, Allen S., Schneider, Daniel J., Abeloff, Martin D., Henderson, I. Craig, Muss, Hyman B., Green, Stephanie I., Lew, Danika, Livingston, Robert B., Martino, Siluana, and Osborne, C. Kent
- Subjects
- *
DRUG efficacy , *DRUG therapy , *ADJUVANT treatment of cancer , *TAMOXIFEN , *ANTINEOPLASTIC agents , *BREAST cancer treatment , *CANCER in women , *CANCER treatment - Abstract
The article focuses on a parallel, randomised trial which assessed the benefit of adding chemotherapy to adjuvant tamoxifen and whether tamoxifen should be given concurrently or after chemotherapy in postmenopausal women with endocrine-responsive, node-positive breast cancer. The patients used in the study were randomly assigned by a computer algorithm. An analysis by intention was also conducted to treat eligible patients. Findings revealed the effectiveness of chemotherapy with cyclophosphamide, doxorubicin and fluorouracil (CAF) plus tamoxifen given sequentially than adjuvant therapy.
- Published
- 2009
- Full Text
- View/download PDF
12. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer.
- Author
-
Hughes, Kevin S., Schnaper, Lauren A., Berry, Donald, Cirrincione, Constance, McCormick, Beryl, Shank, Brenda, Wheeler, Judith, Champion, Lorraine A., Smith, Thomas J., Smith, Barbara L., Shapiro, Charles, Muss, Hyman B., Winer, Eric, Hudis, Clifford, Wood, William, Sugarbaker, David, Henderson, I. Craig, and Norton, Larry
- Subjects
- *
LUMPECTOMY , *CANCER treatment , *BREAST cancer surgery , *CANCER in women , *TAMOXIFEN , *ESTROGEN antagonists , *WOMEN'S health - Abstract
Background: In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy. Methods: Between July 1994 and February 1999, we randomly assigned 636 women who were 70 years of age or older and who had clinical stage I (T1N0M0 according to the tumor–node–metastasis classification), estrogen-receptor–positive breast carcinoma treated by lumpectomy to receive tamoxifen plus radiation therapy (317 women) or tamoxifen alone (319 women). Primary end points were the time to local or regional recurrence, the frequency of mastectomy for recurrence, breast-cancer–specific survival, the time to distant metastasis, and overall survival. Results: The only significant difference between the two groups was in the rate of local or regional recurrence at five years (1 percent in the group given tamoxifen plus irradiation and 4 percent in the group given tamoxifen alone, P<0.001). There were no significant differences between the two groups with regard to the rates of mastectomy for local recurrence, distant metastases, or five-year rates of overall survival (87 percent in the group given tamoxifen plus irradiation and 86 percent in the tamoxifen group, P=0.94). Assessment by physicians and patients of cosmetic results and adverse events uniformly rated tamoxifen plus irradiation inferior to tamoxifen alone. Conclusions: Lumpectomy plus adjuvant therapy with tamoxifen alone is a realistic choice for the treatment of women 70 years of age or older who have early, estrogen-receptor–positive breast cancer. N Engl J Med 2004;351:971-7. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.